This award recognized LEQEMBI as “a world-first treatment for early AD developed in Japan which selectively binds to and clears neurotoxic substances (abnormal proteins), thereby reducing the rate of ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...

In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

One key factor, however, is that anti-pyroglutamate amyloid antibodies seem to reduce the risk of neuroinflammation – potentially reducing side effects that have been seen with Leqembi and ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Functional and structural studies of two potent antibodies isolated from individuals exposed only to ancestral SARS-CoV-2, demonstrating broad neutralization against the latest SARS-CoV-2 variants ...